Skip to main content
. Author manuscript; available in PMC: 2020 Aug 19.
Published in final edited form as: Br J Haematol. 2009 Oct 11;148(1):99–109. doi: 10.1111/j.1365-2141.2009.07939.x

Fig 5.

Fig 5.

(A) Representative Bcl-2 immunoblot of GRANTA-519 cells 48 h after transfection with BCL2 siRNA or non binding control siRNA. Anti ß actin blotting was used as control. (B) 48 h after transfection of non binding control siRNA (GRANTA-519/ctr. siRNA) and BCL2 siRNA (GRANTA-519/BCL-2 siRNA) GRANTA-519 cells were cultured in the presence of BL22 at the indicated concentration for 48 h. Phosphatidylserine exposure was measured using the annexin V assay. The mean percentage of viable cells (annexin – and PI- negative) ± SEM of three different experiments is shown. Paired t-tests were performed to test for differences between GRANTA-519/t control and GRANTA-519/t BCL2 siRNA cells (*). *indicates when the difference between the cells was statistically significant (P < 0·05) (*: P 0·012). (C) GRANTA-519 cells transfected with non binding control siRNA and BCL2 siRNA were analysed by DIOC(C6) staining upon incubation with BL22 in a concentration of 100 ng/ml for 48 h. The amount of intact mitochondrial membrane potential is shown as the mean percentage of viable cells (annexin – and PI- negative) ± SEM of three different experiments (#: P 0·003).